Essential thrombocythaemia treatment options: addressing patient-specific needs.
Birgegård
Gunnar
G
Department of Haematology, University Hospital, Uppsala, Sweden. gunnar.birgegard@medsci.uu.se
D019468:Disease Management; D006301:Health Services Needs and Demand; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D010976:Platelet Count; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012307:Risk Factors; D013920:Thrombocythemia, Essential / Q000188:drug therapy*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011799:Quinazolines; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C021139:anagrelide; C100416:peginterferon alfa-2a; D006918:Hydroxyurea